| 1958 | December | Manufacturing of Laennec approved with indication of “Cirrhosis” |
| 1967 | July | National Health Insurance (NHI) price listed |
| 1970 | October | Established Japan Bio Products Co., Ltd. (Capital 5 million Yen) |
| December | Increased capital 20 million Yen |
| 1971 | January | Authorized capital of 160,000 shares (worth 80 million Yen) |
| March | Completed Manufacturing plant in Higashikushiharamachi, Kurume-shi, Fukuoka |
| 1974 | August | Increased capital 45 million Yen |
| 1975 | October | Completed new manufacturing plant in Nonakamachi, Kurume-shi, Fukuoka |
| 1984 | October | Re-evaluation of drug efficacy, indication expanded for ”Improvement of hepatic function in chronic liver diseases” |
| 1996 | May | Completed New Kurume-shi manufacturing plant |
| 2004 | April | Established Placenta-Avenir Research Institute (PARI) (current R&D center) |
| 2005 | April | Completed Eumseong manufacturing plant in Korea |
| 2006 | September | Established JBP China Co., Ltd. |
| 2007 | September | Acquired full ownership of Japan Bio Products Co., Ltd. |
| 2011 | September | Acquired full ownership of Nissei Souken Co., Ltd. (capital 55 million Yen) |
| 2015 | April | Completed L’Atelier Fujimitsu Kurume Plant in Fujimitsu machi, Kurume-shi, Fukuoka |
| 2016 | June | Increased capital 25 million Yen |
